Fulcrum Files S-4 for Slate Medicines Reverse Merger: $270M Dividend, 5% Ownership for Existing Holders
FULC sits 34% above its 52-week low of $2.83.
Summary
Fulcrum Therapeutics filed its S-4 for the reverse merger with Slate Medicines, providing complete terms: $270M pre-closing dividend to existing holders, 5% ownership in the combined company, $245M concurrent investment, and a reverse stock split to maintain Nasdaq listing.
Key Events · M&A and Partnerships · FULC
-
Reverse Merger with Slate Medicines
Fulcrum will merge with Slate Medicines in an all-stock deal valuing Slate at $350M, with existing Fulcrum stockholders retaining approximately 5% ownership in the combined company.
-
$270M Pre-Closing Cash Dividend
Fulcrum stockholders will receive approximately $270M in a special cash dividend before closing, representing the bulk of Fulcrum's $318.8M cash balance.
-
$245M Slate Concurrent Investment
Slate secured $245M in concurrent financing from existing and new investors including Frazier Life Sciences, with investors expected to own 39.1% of the combined company.
-
Reverse Stock Split Proposal
Stockholders must approve a reverse stock split at a ratio to be determined by the board to maintain the $4.00 minimum bid price required for Nasdaq listing.
Analysis · FULC · Life Sciences
The formal S-4 registration statement for the reverse merger with Slate Medicines has been filed, laying out the complete definitive terms of a transaction that will fundamentally transform the company. Existing Fulcrum stockholders are set to receive approximately $270 million in a pre-closing cash dividend and retain roughly 5% ownership in the combined company, which will be renamed Slate Medicines and trade under the ticker SLTE. The filing discloses an estimated exchange ratio of 24.8186 Fulcrum shares per Slate share, a $245 million concurrent investment led by Frazier Life Sciences, and a proposed reverse stock split to maintain Nasdaq listing compliance. This marks the culmination of a strategic alternatives process that began after Fulcrum discontinued its pociredir program in June 2026 and cut 85% of its workforce. The S-4 provides the first complete picture of the transaction mechanics, including the Leerink Partners fairness opinion, termination fees, and the detailed negotiation history showing Fulcrum evaluated 62 potential counterparties before selecting Slate.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.1% of the 372 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FULC was trading at $3.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $295.3M. The 52-week trading range was $2.83 to $15.74. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.